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Background: Studies using allergen challenge models have suggested Th2 cytokines promote
airway inflammation in asthma. We assessed mediators of airway inflammation during the
chronic asymptomatic phase of asthma.
Methods: Nine non-atopic asthma (NAA) patients, 19 atopic asthma (AA) patients, 20 atopic
controls (AC), and 38 normal controls (NC) underwent sputum induction while asymptomatic.
Sputum total cell counts and differentials were determined; levels of cytokines IL-4, IL-5, IL-
13, GM-CSF, and IFN-g, and chemokines eotaxin (CCL11) and RANTES (CCL5) were measured by
ELISA; and levels of eosinophil-derived neurotoxin (EDN) were measured by radioimmunoassay.
Results: NAA patients showed higher % eosinophils and total eosinophils compared to AA. NAA
and AA patients showed higher IFN-g and EDN levels compared to AC and NC, with no differ-
ences in IL-4, IL-5, or IL-13 levels among the four groups. GM-CSF levels were higher in AA
patients compared to AC or NC. In NAA, AA, and AC patients, % eosinophils and EDN levels
correlated positively with IFN-g, GM-CSF, eotaxin, and RANTES, but not with IL-5 levels.
Conclusions: Baseline airway inflammation of intrinsic and extrinsic asthma is characterized by
eosinophilic inflammation and the Th1 cytokine, IFN-g. GM-CSF, instead of IL-5, and chemo-
kines may coordinate airway eosinophilia during the chronic asymptomatic phase of asthma.
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It has been known for over 100 years that the eosinophil is
associated with bronchial asthma.1 Over the past two
decades, the underlying airway inflammation of asthma,
characterized by marked infiltration of eosinophils, has
received increasing attention. Numerous human airway
studies have provided consistent evidence for the strong
Airway eosinophilia during chronic asymptomatic asthma 1437association between the inflammatory nature of asthma
and airway eosinophils.2,3 Eosinophil granular proteins,
such as eosinophil major basic protein and eosinophil
peroxidase, have functions relevant to the features of
human asthma, including histopathologic changes, revers-
ible airway narrowing, and bronchial hyperreactivity.4,5
Thus, evidence supports a central role for eosinophils in
the pathophysiology of bronchial asthma. However, the
precise mechanism of airway eosinophil involvement in
asthma remains enigmatic.
Over the last decade, interest has been focused on the
Th1/Th2 paradigm in the pathogenesis of asthma. Th2 cells
mediate eosinophil influx by releasing Interleukin (IL)-4 and
IL-56; IL-5 is the major eosinophil specific growth factor.
Indeed, an increase in Th2 cytokine production in the
airway has been found in asthma.7 However, the role of
eosinophils as effector cells in asthma pathogenesis has
been questioned. Leckie et al.8 showed anti-IL-5 Ab treat-
ment of patients with asthma decreased blood and sputum
eosinophils but did not affect the late asthmatic responses
and airway hyperresponsiveness. These results from the
allergen challenge model are difficult to interpret, since
they do not necessarily reflect events in the natural course
of asthma. This was clearly demonstrated in a study by
Lommatzsch et al.9 who found eosinophil and lymphocyte
infiltration into the airways occurred at significantly
different times when comparing human and murine asthma.
More recent studies by Haldar et al.10 and Nair et al.11
demonstrated reductions in eosinophil numbers and clin-
ical improvement after administration with anti-IL-5 Ab
treatment of patients with refractory eosinophilic asthma.
Intrinsic (non-atopic) asthma is considered a variant of
asthma, since unlike extrinsic (atopic) asthma, patients with
the disease are skin test-negative to common aeroallergens,
lack circulating specific IgE, and have later clinical onset.12
Analyses of airway specimens in patients with extrinsic
asthma have revealed the activation of typical Th2 lympho-
cytes producing IL-4 and IL-5, but no IL-2 or interferon (IFN)-
g.13,14 In contrast, intrinsic asthma appears to have a more
distinct T-cell activation pattern, producing IL-5, IL-2 and
IFN-g, but not IL-4, which is incompatible with a typical Th2
pattern.15,16 However, recent studies indicate more simi-
larities than differences in regard to cytokine gene expres-
sion between intrinsic and extrinsic asthma.17
The aim of the present study was to compare intrinsic and
extrinsic asthma in terms of their patterns of eosinophilic
inflammation and cytokine profiles (Th1 or Th2) in the
airway. To perform the study, we examined eosinophils,
eosinophil-associated cytokines (IL-4, IL-5, IL-13, IFN-g, and
GM-CSF) and chemokines eotaxin (CCL11) andRANTES (CCL5)
in sputum from intrinsic and extrinsic asthmatic subjects
during a stable period of natural asthma. These results were
compared with those of atopic and normal control subjects.
Methods
Study subjects
Induced sputum was obtained from nine non-atopic asth-
matic (NAA), 19 atopic asthmatic (AA), 20 nonasthmatic
atopic control (AC), and 38 nonasthmatic non-atopic normalcontrol (NC) subjects. At the time of study, asthmatic
patients had stable bronchial asthma, with no acute asthma
symptoms nor evidence of chest infection. Fifteen out of 20
AC subjects had a history of allergic rhinitis. All subjects
underwent sputum induction during the winter time. All
subjects were nonsmokers and had not taken oral gluco-
corticoids for at least 8 weeks prior to the study. Four out of
9 NAA subjects and 9 out of 19 AA subjects were receiving
regular inhaled corticosteroid therapy. Subjects were
recruited from a pool of patients or healthy individuals seen
at the Mayo Clinic, Rochester, MN. The Mayo Clinic Insti-
tutional Review Board reviewed and approved this study.
Asthmatic subjects had a clear history of asthma. They
had a greater than 15% increase in FEV1 after 180 mg inhaled
albuterol and/or a positive methacholine challenge as
defined by a 20% reduction from baseline in FEV1 following
inhaled methacholine.
Atopy was defined as the presence of at least one posi-
tive skin prick reaction (>3 mm wheal diameter) to
a battery of 15 common aeroallergens. Nonatopic subjects
had negative skin test responses to the battery of 15
common aeroallergens, and negative RAST test responses
(Pharmacia Diagnostics, Uppsala, Sweden) to the same
common aeroallergens.
Sputum induction
All subjects were pre-medicated with 2 puffs of albuterol,
total dose 180 mg, via spacer tube. Sputum induction was
performed with aerosolized 3% hypertonic saline solution
generated by a DeVilbiss Ultra-Neb 99 ultrasonic nebulizer
(the DeVilbiss Co, Somerset, PA), as described previously.18
Sputum processing
The collected sputum was processed, as described by Piz-
zichini et al.19 with modifications. Sputum was processed
immediately within a time limit of 2 h. Equal volumes of
sputum were placed into two 15-ml polypropylene tubes.
One aliquot was treated with an equal volume of saline
solution containing 0.1% dithiothreitol (DTT) (1:10 diluted
DTT) (Sputolysin 1%; Calbiochem Corp., San Diego, CA)
(“with DTT” aliquot). The other aliquot was mixed with two
times the volume of saline solution without DTT (“without
DTT” aliquot). Both mixtures were aspirated up and down
with a Pasteur pipette, then vortexed for 15 s, and placed
on a bench rocker for 20 min “with DTT” aliquots were
filtered through 40-mm strainers (Beckton Dickinson,
Franklin Lakes, NJ) and then both aliquots were centrifuged
at 833 g for 10 min at 4 C. The supernatants from each
sample were collected and then frozen at 70 C for later
assays. Cell pellets from the original aliquot “with DTT”
were resuspended in saline solution, stained with trypan
blue and a total nonsquamous cell count was performed
with a hemocytometer. A nonsquamous cell viability was
then calculated. Cytospin preparations were adjusted to
equal approximately 1.0  106/ml, and then stained with
Diff-Quik stain (Dade Behring Inc., Newark, DE). Four
hundred differential nonsquamous cells were counted. The
specimen was considered adequate if morphologic identi-
fication of total and differential cell counts could be
obtained.20 Individual cell number/ml was determined by
1438 C.K. Kim et al.multiplying the percentage specific cell type by the total
cell number/ml. Supernatant “with DTT” aliquot and cell
pellet “without DTT” were not used in this study.
Fluid-phase markers measurements
The levels of IL-4, IL-5, IL-13, IFN-g (Endogen, Woburn, MA),
GM-CSF, eotaxin andRANTES (R&DSystems,Minneaplois,MN)
were measured in the thawed supernatant using sandwich
ELISAs according to the respectivemanufacturers’ protocols,
and the results were expressed in pg/ml. The sensitivities for
IL-4 and IL-5were less than2.0 pg/ml and those for IL-13, IFN-
g, GM-CSF, eotaxin and RANTES were less than 10 pg/ml,
1 pg/ml, 0.36 pg/ml, 5.0 pg/ml, and 2.5 pg/ml, respectively.
The eosinophil-derived neurotoxin (EDN) value was deter-
mined using a double antibody competitive RIA and the
results were expressed in ng/ml. The sensitivity for EDN was
less than 1 ng/ml. The result was adjusted for the dilution.
When cytokine and chemokine levels were below sensitivity,
0 level was used for comparisons of the levels and 1/2 level of
the sensitivity was used for correlations.
Statistical analysis
Cellularity and fluid-phase marker levels were presented as
medians with interquartile ranges [25the75th]. Fluid-phase
marker levels were analyzed only in the “without DTT”
aliquot. Because most of the data were not normally
distributed, differences between the four subject groups
were screened with the nonparametric KruskaleWallis test.
When this test indicated a significant difference, the
difference between two groups was tested for significance
with a ManneWhitney U test. Correlations were analyzed
by the nonparametric Spearman correlation test. A P value
of <0.05 was considered statistically significant.
Results
Subject characteristics
Subject characteristics are as follows: 1) age [median(range)]:
NA, 44 (23e71 yr); AA, 28 (22e44); AC, 35 (22e70); NC, 36.5
(22e75); 2) sex (M:F): NA, 1:8 (P < 0.05 compared to AA); AA,
11:8; AC, 6:14; NC, 12:26; 3) FEV1 (% predicted) [median
(range)]: NA, 92 (61e116); AA, 96 (68e114); AC, 101 (83e118);
NC, 103 (90e122); 4) FEV1FVC (%) [median(range)]: NA, 83
(54e101); AA, 90 (64e104); AC, 87 (60e111); NC, 91 (80e104);
5) patients on inhaled corticosteroids: NA, 4/9; AA, 9/19; AC,
0/20;NC,0/38.All subjects toleratedsputuminductionwithno
adverseeffects.Three subjectswereexcluded: twobecauseof
poor sputum induction (oneAAandoneNC) and one because of
a low FEV1% predicted (NC). There were significantly more
womenamongNAA(P<0.05) subjects thanamongAAsubjects.
There were no statistical differences between the four groups
in terms of age, FEV1% predicted, or FEV1/FVC ratio.
Cell and mediator profiles
Cell viability, the number of total cells per ml, and the
percentages for each cell type in induced sputum are shownin Table 1. No differences were found in cell viability.
Numbers of total cells were significantly higher in NAA
subjects compared with AA (P < 0.05), AC (P < 0.05), and
NC (P < 0.01) subjects. With regard to cell types, there
were significant differences in the percentages of macro-
phages, eosinophils, and epithelial cells among the 4
groups. Eosinophil percentages were significantly higher in
NAA subjects than AA (P < 0.01) and AC/NC (P < 0.001)
subjects. In AA subjects, eosinophil percentages were
higher than in AC/NC subjects. Epithelial cells percentages
were significantly higher in AA subjects than in NAA
(P < 0.01), AC (P < 0.05), and NC (P < 0.01) subjects.
Percentage of macrophages was lower in NAA (P < 0.01)
subjects than in NC subjects, in conjunction with a marked
increase in the percentage of eosinophils. Percentages of
neutrophils and lymphocytes showed no significant differ-
ences among the 4 groups.
Absolute numbers of eosinophils and levels of EDN from the
four groups are shown in Fig. 1-A and Fig. 1-B. A significant
increase in the absolute eosinophil number was evident in
asthmatic subjects (NAA and AA) compared with control
subjects (AC and NC; P < 0.001, P < 0.0001, P < 0.01,
P< 0.0001, respectively). Between the two asthmatic groups,
NAA subjects showed significantly higher eosinophil absolute
numbers compared to AA subjects (P < 0.01). Similarly,
between the two control groups, AC subjects showed signifi-
cantly higher eosinophil absolute numbers compared to NC
subjects (P < 0.05). Absolute numbers of macrophages,
neutrophils, lymphocytes and epithelial cells showed no
significant differences among the 4 groups.
A significant increase in EDN levels was also evident in
asthmatic subjects (NAA and AA) compared with control
subjects (AC and NC). Between the two asthmatic groups,
NAA subjects showed higher EDN levels than AA subjects,
although the difference did not reach statistical signifi-
cance (P Z 0.068). No differences in EDN levels were
detected between AC and NC subjects.
Cytokine profiles
IL-4, IL-5, IL-13, GM-CSF and IFN-g levels in the 4 groups were
compared. No differences were observed in sputum levels of
IL-4, IL-5, or IL-13 among the four groups (data not shown).
GM-CSF levels (Fig. 2-A)were higher in NAA (1.7[0.0e2.2] pg/
ml) and AA (1.8[1.2e2.7] pg/ml) patients compared to AC
(0.0[0.0e1.5] pg/ml) and NC (1.3[0.0e1.7] pg/ml) subjects,
although statistical significance was only reached in AA
(P< 0.01) patients. IFN-g levels (Fig. 2-B) were higher in NAA
(16.5[14.9e18.5] pg/ml) and AA (20.9[14.5e25.8] pg/ml)
patients compared to AC (0.0[0.0e6.6] pg/ml, P< 0.001 and
P < 0.0001) and NC (5.5[0.0e10.5] pg/ml, P < 0.001 and
P < 0.0001) subjects. The ratios of IFN-g/IL-4 (not shown),
IFN-g/IL-5 (Fig. 2-C) and IFN-g/IL-13 (Fig. 2-D) were similarly
higher in NAA and AA patients compared to AC and NC
subjects. No differences were found between the two
asthma groups or between the two control groups.
Chemokine profiles
Comparisons of eotaxin and RANTES levels in the 4 groups are
shown in Fig. 3A and B. Only NAA (94.4[70.7e129.1] pg/ml)
Table 1 Sputum cell profiles of study subjects.a
Non-atopic
asthma (n Z 9)
Atopic asthma
(n Z 19)
Atopic control
(n Z 20)
Normal control
(n Z 38)
Viability, % 77.0 [76.0e85.3] 77.4 [69.8e85.0] 85.2 [72.5e88.5] 80.0 [71.8e84.3]
Total cells, 105/ml 11.0yzx [7.7e13.0] 7.0 [5.3e8.1] 7.0 [4.3e9.6] 6.3 [3.7e7.6]
Macrophages, % 35.0x [21.5e41.5] 55.0 [30.0e66.5] 57.3 [30.3e68.0] 58.8 [46.3e68.5]
Neutrophils, % 22.0 [12.8e47.5] 18.0 [9.0e34.0] 29.8 [18.5e58.8] 28.0 [17.0e48.6]
Lymphocytes, % 3.0 [1.3e7.5] 3.0 [1.5e4.5] 3.0 [1.1e4.8] 2.5 [1.0e6.0]
Eosinophils, % 24.0{#** [14.0e48.3] 8.0#** [2.5e21.0] 1.3x [0e2.8] 0 [0e1.0]
Epithelial cells, % 1.5{ [1.0e2.8] 8.5zx [2.0e21.5] 4.5 [1.3e8.0] 3.5 [0.9e6.0]
yP < 0.05 compared with Atopic asthma.
zP < 0.05 compared with Atopic control.
xP < 0.01 compared with Normal control.
{P < 0.01 compared with Atopic asthma.
#P < 0.001 compared with Atopic control.
**P < 0.001 compared with Normal control.
a Data are expressed as median and interquartile range [25the75th].
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[22.8e70.8] pg/ml, P < 0.01), AC (33.4[18.6e51.7] pg/ml,
P< 0.001), and NC (37.5[21.4e50.4] pg/ml, P< 0.0001). NAA
(17.8[0e32.3] pg/ml) and AA (12.2[0e35.7] pg/ml) patients
showed higher RANTES levels compared to NC (0[0e9.3] pg/
ml) (P < 0.05). No differences were found between the two
asthma groups or between the two control groups.
Correlations
Correlations of cytokines IL-4, IL-5, IL-13, IFN-g and GM-CSF
and the chemokines eotaxin and RANTES with sputum
eosinophils and EDN in NAA, AA, and AC subjects are shown
in Table 2. Percentage of sputum eosinophils and EDN levels
correlated positively with the levels of IFN-g (rZ 0.606 and
p < 0.0001, r Z 0.432 and p < 0.01), GM-CSF (r Z 0.541
and p < 0.0001, rZ 0.453 and p< 0.01), eotaxin (rZ 0.640
and p < 0.0001, r Z 0.514 and p < 0.001), and RANTES
(rZ 0.506 and p < 0.001, rZ 0.480 and p < 0.001), but not
with IL-4, IL-5, and IL-13 levels.Figure 1 Absolute numbers of sputum eosinophils (Fig. 1-A) and
expressed as box and whisker plots with range and values displayeDiscussion
Measurement of mediators in an allergen challenge model
or during acute exacerbation of asthma has been used
widely to elucidate the roles of inflammatory mediators
and cytokines in asthma patients. However, these models
may not reflect the mechanism of chronic disease because
of the acute exposure to extremely high concentrations of
allergen. Therefore, we assessed airway inflammation in
sputum from intrinsic and extrinsic asthmatics during their
stable period of chronic asthma. In this study, we observed
that NAA and AA patients had higher sputum eosinophils (%
and total) and EDN levels compared to AC and NC. No
differences were observed in IL-4, IL-5, and IL-13 levels
among the four groups. In contrast, IFN-g levels were
higher in NAA and AA patients compared to AC and NC. GM-
CSF levels were higher in AA patients compared to AC and
NC. NAA and AA patients showed higher RANTES levels
compared to NC; NAA patients showed higher eotaxin levels
compared to AA, AC, and NC. The percentage of sputumsputum EDN (Fig. 1-B) levels from the four groups. Levels are
d. Dot lines represent the sensitivity levels of the EDN assay.
Figure 2 Comparisons of sputum cytokines GM-CSF (2-A) and IFN-g (Fig. 2-B) levels in the 4 groups, including IFN-g/IL-5 (Fig. 2-C)
and IFN-g/IL-13 (Fig. 2-D) ratios. Levels are expressed as box and whisker plots with range and values displayed. Dot lines represent
the sensitivity levels of the assay.
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levels of IFN-g, GM-CSF, RANTES and eotaxin, but not with
IL-5 levels. Thus, these sputum findings demonstrate that
the baseline airway inflammation of asthma, irrespective of
atopic or non-atopic diathesis, is characterized by eosino-
philic inflammation and a Th1 cytokine, IFN-g. GM-CSF,
instead of IL-5, and chemokines may coordinate airway
eosinophilia during the asymptomatic period of chronic
asthma. Between non-atopic asthma and atopic asthma,Figure 3 Comparisons of sputum eotaxin (Fig. 3-A) and RANTES (
whisker plots with range and values displayed. Dot lines representthe only differences were in sputum eosinophils and
eotaxin. There was no qualitative difference between the 2
groups in terms of mediators.
A potential pitfall of our study was the difficulty in
optimal measurement of the fluid-phase markers. There is
currently no consensus among researchers as to whether
DTT or protease inhibitors should be used in sputum pro-
cessing. Most authors process sputum with DTT as a muco-
lytic19 that reduces disulfide bonds.21 However, evidenceFig. 3-B) levels in the 4 groups. Levels are expressed as box and
sensitivity levels of the assay.
Table 2 Correlations of sputum cytokines and chemokines with sputum eosinophils and EDN in NAA, AA, and AC patients.
IL-4 IL-5 IL-13 IFN-g GM-CSF Eotaxin RANTES
Eosinophils, % R Z 0.160,
P]NS
R Z 0.099,
P]NS
R Z 0.049,
P]NS
R Z 0.606,
P < 0.0001
R Z 0.541,
P < 0.0001
R Z 0.640,
P < 0.0001
R Z 0.506,
P < 0.001
Eosinophils, total R Z 0.132,
P]NS
R Z 0.130,
P]NS
R Z 0.121,
P]NS
R Z 0.524,
P < 0.0001
R Z 0.273,
P]NS
R Z 0.675,
P < 0.0001
R Z 0.541,
P < 0.0001
EDN R Z 0.201,
P]NS
R Z 0.058,
P]NS
R Z 0.227,
P]NS
R Z 0.432,
P < 0.01
R Z 0.453,
P < 0.01
R Z 0.514,
P < 0.001
R Z 0.480,
P < 0.001
Airway eosinophilia during chronic asymptomatic asthma 1441suggests that DTT has the potential to interfere with the
detection of inflammatory mediators in the sputum fluid
phase, either by affecting the three dimensional structure
of proteins, or by interfering directly with the immuno-
assay.22 Furthermore, we observed that levels of IL-5 and
eotaxin, but not EDN, were significantly lower in “with
DTT” aliquots compared to “without DTT” aliquots (data
not shown). Hence, we analyzed the fluid-phase marker
levels only in the “without DTT” aliquot in the present
study. Sputum proteases may also be responsible for
degrading the mediators or interfering with the antibodies
in the assay in some cases. Proteases may attain high levels
in sputum, proportional to the clinical severity of asthma.23
Kelly et al.24 observed increased detection of IL-5 in sputum
by addition of protease inhibitors. However, we believe this
is not problematic in this study because most fluid-phase
markers including IL-5 were recovered in our assay.
The “Th2 hypothesis for asthma”25 is controversial and
more recent studies suggest it is far too simplistic.26 Animal
studies have shown that Th1 cells do not counterbalance
Th2-mediated effects but may worsen airway inflamma-
tion,27 while human asthma subjects have exhibited
significant increases in IFN-g, with no significant differ-
ences in IL-4 production in the supernatants of cultured
bronchoalveolar cells.28 More recently, Magnan et al.29
demonstrated increased IFN-g-producing CD8þ T cells in
asthmatic airways, and the levels of IFN-g correlated with
asthma severity, bronchial hyperresponsiveness, and blood
eosinophilia. Human eosinophils are known to express and
be activated through the IFN-g receptor.30 These observa-
tions question the concept that Th1 cytokine levels are
decreased in patients with asthma.
Epidemiological studies suggest that allergy and asthma
are not identical.31 Illi et al.32 demonstrated that only
about a third of individuals with allergic rhinitis (caused by
Th2 responses in the upper respiratory tract) develop
asthma (caused by Th2 responses in the lower airways). Our
results indicate the significant increase in a Th1 cytokine,
IFN-g, in both atopic and non-atopic asthma. There were no
significant increases in Th2 cytokines, IL-4, IL-5, or IL-13 in
the two asthma groups, whereas a typical Th2 pattern was
found in AC subjects based on decreased IFN-g/IL-4, IFN-g/
IL-5 and IFN-g/IL-13 ratios. These results are consistent
with the previous observation that IFN-g production prom-
inently appears in chronic phase lesions of atopic derma-
titis.33 In our study, IFN-g levels were higher in non-atopic
and atopic asthmatics when compared to controls, and
correlated with eosinophil-active cytokine GM-CSF and
chemokines eotaxin and RANTES. The increased IFN-g
levels may be due to its release by airway eosinophils,leading to increased eosinophilic infiltration and greater
IFN-g release through autocrine stimulation.30,34 IFN-g also
induces/enhances the expression of intercellular adhesion
molecule-1 (ICAM-1),35 which is important in eosinophil
migration because it plays a critical role in eosinophil
adhesion to endothelial cells in vivo36 and in vitro.37 This
seems plausible as both non-atopic and atopic asthmatics
had significantly greater sputum eosinophils (% and total)
when compared to controls. In a murine model, activated
eosinophils strongly induced IFN-g expression in lungs,
while Th2 inflammatory and regulatory responses, such as
IL-4, IL-6, IL-9, IL-10, IL-13, and TGF-b, were minor or
insignificant.34 Yamaguchi et al.38 found IFN-g significantly
enhanced GM-CSF-induced eosinophil degranulation. Other
studies have shown that IFN-g upregulated RANTES mRNA
and protein expression,39 and enhanced eotaxin expression
in airway epithelial cells.40 Although further confirmation is
required, our sputum findings suggest that both intrinsic
and extrinsic asthma may not follow a typical Th2 pattern,
at least in asymptomatic chronic asthma.
The role of IL-5 in human asthma is not as strong as
previously suspected. There are several reasons for low IL-5
or lack of difference in IL-5 levels between asthmatic and
nonasthmatic patients other than protease activity, inhaled
steroid use or asymptomatic phase of asthma. First, Flood-
Page et al.41 observed that anti-IL-5 only reduced airway
tissue eosinophils by 50%. Furthermore, the level of eosin-
ophilic degranulation (MBP) within the bronchial mucosa
remained unchanged by anti IL-5 treatment. Second, Liu
et al.42 suggested that when eosinophils are recruited to
the airway, regulation of their function becomes IL-5
independent. There was a striking reduction in membrane
IL-5Ra on BAL eosinophils compared to blood eosinophils; in
contrast, membrane GM-CSFRa was expressed on nearly
100% of BAL eosinophils. Furthermore, Hamilos et al.43
observed that GM-CSF mRNA, but not IL-5, was increased
in chronic sinusitis with nasal polyposis and the degree of
tissue eosinophilia most strongly associated with GM-CSF,
not IL-5. GM-CSF activates mature eosinophils, increasing
their degranulation, cytotoxicity, and response to chemo-
attractants. It is particularly important because mature,
activated eosinophils lose their expression of IL-5Rs, while
upregulating GM-CSF receptors; consequently, it is essential
to prolonging eosinophil survival and function.44 These data
raise the possibility that airway eosinophils are less
dependent on IL-5 for recruitment and degranulation, and
that GM-CSF may play a more prominent role by prolonging
the survival and function of eosinophils in the airways. In
partial contrast, a recently published study by Fanat
et al.45 found anti-IL-5 and GM-CSF therapy reduced the
1442 C.K. Kim et al.eosinophilopoietic potential of airway smooth muscle cells,
suggesting they may promote in situ eosinophilopoiesis in
asthmatic lungs. As well, Haldar et al.10 and Nair et al.11
demonstrated the ability of anti-IL-5 therapy to reduce
eosinophil numbers and asthma control in refractory
eosinophilic asthma. It should be noted, however, in our
study the lack of IL-5 in sputum during chronic asymptom-
atic asthma does not rule out its contribution to airway
eosinophilia, as it may prime circulating eosinophils prior to
their egress to the airway.
In this study,GM-CSF, IFN-g, eotaxin andRANTESebut not
IL-5 e correlated strongly with the percentage of sputum
eosinophils. Therefore, we suggest that GM-CSF, instead of
IL-5, and chemokines may coordinate airway eosinophilia
during the chronic asymptomatic phase of asthma.
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